PlainPharmaWatch

CMS Open Payments · Tool

Paratek Pharmaceuticals, Inc. vs Biotissue Holdings Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Paratek Pharmaceuticals, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 302, versus 90 for the other company. Its single largest recorded recipient represents 0.1% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Paratek Pharmaceuticals, Inc.
HHI 302 · top recipient 0.1%
Ranked #1,460 of 1,838 companies by HHI
Biotissue Holdings Inc.
HHI 90 · top recipient 0.0%
Ranked #1,703 of 1,838 companies by HHI

Payment Overview

Total Payments
$3.3M
% of Industry
0.0%
Transactions
23,378
Avg per Transaction
$142.07
Recipients
23,113
Avg per Recipient
$143.69
Payment Types
9
Top Payment Type
Food and Beverage
Total Payments
$3.3M
% of Industry
0.0%
Transactions
21,216
Avg per Transaction
$156.83
Recipients
20,909
Avg per Recipient
$159.14
Payment Types
4
Top Payment Type
Food and Beverage

Highlighted values indicate the higher figure for each metric.

Total payments compared

Paratek Pharmaceuticals, Inc. vs Biotissue Holdings Inc. - total reported payments in CMS Open Payments PY2024

Biotissue Holdings Inc.$3.3MParatek Pharmaceuticals, In…$3.3M

Payment Types Breakdown

Paratek Pharmaceuticals, Inc.

Food and Beverage $514.1K

15.5%

Compensation for Services Other Than Consulting $408.8K

12.3%

Travel and Lodging $196.6K

5.9%

Consulting Fee $112.4K

3.4%

Space Rental or Facility Fees $9.0K

0.3%

Grant $5.0K

0.2%

Biotissue Holdings Inc.

Food and Beverage $902.3K

27.1%

Consulting Fee $689.1K

20.7%

Travel and Lodging $270.3K

8.1%

Compensation for Faculty or Speaker (Medical Education) $227.1K

6.8%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Paratek Pharmaceuticals, Inc.

  1. 1

    ANDREW DOLD

    $155,391.51 · 223 txns

  2. 2

    YOAV GOLAN

    $86,119.53 · 80 txns

  3. 3

    WARREN JOSEPH

    $76,196.43 · 66 txns

  4. 4

    DAVID WU

    $59,150.00 · 12 txns

  5. 5

    HECTOR BRUNET RODRIGUEZ

    $30,579.11 · 46 txns

Biotissue Holdings Inc.

  1. 1

    NEEL RAJENDRA DESAI

    $101,652.27 · 26 txns

  2. 2

    MICHAEL JAMES BAUER

    $72,055.00 · 11 txns

  3. 3

    BRIAN J BEAR

    $53,141.73 · 11 txns

  4. 4

    JASON DOUGLAS BULLAJIAN

    $50,204.86 · 47 txns

  5. 5

    BRETT BIELORY

    $49,386.99 · 64 txns

Summary Comparison

Metric Paratek Pharmaceuticals, Inc. Biotissue Holdings Inc.
Total Payments $3.3M $3.3M
% of Industry Total 0.0% 0.0%
Transaction Count 23,378 21,216
Avg per Transaction $142.07 $156.83
Recipient Count 23,113 20,909
Avg per Recipient $143.69 $159.14
Payment Type Count 9 4
Top Payment Type Food and Beverage Food and Beverage

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.